SLC18A2 and depressive disorder: Deutetrabenazine treatment was generally well tolerated, with most AEs considered mild or moderate in severity and low incidences of AEs commonly observed in patients with TD and VMAT2 inhibitor class–related AEs, including depression and parkinsonism.